In ATEMPT, adjuvant T-DM1 was associated with superior overall HRQOL, lower risk of neuropathy and superior work productivity, while maintaining excellent 3-year iDFS in patients with stage I HER2-positive breast cancer4. This evidence concerns the gene ERBB2 and neuropathy.